(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -4.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Biontech Se's revenue in 2025 is $3,120,795,454.On average, 3 Wall Street analysts forecast BNTX's revenue for 2025 to be $813,747,295,309, with the lowest BNTX revenue forecast at $486,109,940,577, and the highest BNTX revenue forecast at $1,014,896,783,338. On average, 7 Wall Street analysts forecast BNTX's revenue for 2026 to be $652,924,390,799, with the lowest BNTX revenue forecast at $409,549,698,323, and the highest BNTX revenue forecast at $859,300,254,823.
In 2027, BNTX is forecast to generate $646,851,111,596 in revenue, with the lowest revenue forecast at $421,172,681,596 and the highest revenue forecast at $854,432,304,227.